[基于乙甲脱酶2基因多态性和乙氨基诱导的肝损伤的研究]
1Digestive Medicine Center, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China.
概括
脱酶2 (ALDH2) 基因变异与乙氨基 (APAP) 诱导的肝损伤有关. 在暴露于APAP后,ALDH2淘汰赛小鼠显示肝损伤增加,这表明ALDH2具有保护作用.
科学领域:
- 药物基因组学 药物基因组学
- 毒理学 毒理学 毒理学
- 遗传学 是一个遗传学.
背景情况:
- 乙氨基 (APAP) 是一种常见的药物,可能导致肝损伤.
- 化脱酶2 (ALDH2) 是一种参与代谢有毒物质的酶.
- ALDH2的遗传变异可能会影响对药物诱导的肝损伤的敏感性.
研究的目的:
- 为了研究ALDH2基因多态和乙氨基诱导的肝功能障碍之间的关联.
- 评估ALDH2基因淘汰对小鼠模型中乙氨基毒性的影响.
主要方法:
- 使用CRISPR/Cas9技术创造了ALDH2淘汰小鼠.
- 乙氨基被用于诱导野生类型和ALDH2淘汰赛小鼠的急性肝损伤.
- 进行了肝功能测试,组织学检查 (HE染色) 和免疫组织化学 (F4/80) 测试.
主要成果:
- 与野生类型小鼠相比,ALDH2淘汰小鼠在服用APAP后表现出明显升高的肝酶 (ALT,AST,TBil) 和增加的肝损伤.
- 组织学分析显示,在ALDH2突变小鼠中,肝细胞退化,亡和炎症更严重.
- 在APAP治疗的突变小鼠中,F4/80表达,表明巨细胞透,显着更高.
结论:
- ALDH2基因多态性与对乙氨基诱导的肝损伤的易感性变化有关.
- 缺少ALDH2会加剧APAP引起的肝毒性,凸显了该酶的保护作用.
- 向ALDH2可能为治疗药物诱导的肝损伤提供治疗策略.
相关概念视频
Phase II Reactions: Acetylation Reactions
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...


